Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ELDN

ELDN - Eledon Pharmaceuticals, Inc. Stock Price, Fair Value and News

$2.12-0.08 (-3.64%)
Market Closed

Price Targets

ELDN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ELDN Price Action

Last 7 days

-3.6%

Last 30 days

36.8%

Last 90 days

-51.3%

Trailing 12 Months

-55.3%

ELDN RSI Chart

ELDN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ELDN Valuation

Market Cap

127.1M

Price/Earnings (Trailing)

-1.59

Price/Sales (Trailing)

718.31

EV/EBITDA

-2.63

Price/Free Cashflow

-1.89

ELDN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

ELDN Fundamentals

ELDN Revenue

Revenue (TTM)

136.0K

ELDN Earnings

Earnings (TTM)

-79.8M

Earnings Growth (Yr)

-122.68%

Earnings Growth (Qtr)

-55.66%

ELDN Profitability

EBT Margin

-26288.97%

Return on Equity

-225.64%

Return on Assets

-61.44%

Free Cashflow Yield

-52.92%

ELDN Investor Care

Shares Dilution (1Y)

0.32%

Diluted EPS (TTM)

0.37

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2017136.0K000
2016188.0K212.0K196.0K164.0K
2015168.0K170.0K172.0K174.0K
2014000166.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Eledon Pharmaceuticals, Inc.

ELDN
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
 CEO
 WEBSITEhttps://eledon.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES17

Eledon Pharmaceuticals, Inc. Frequently Asked Questions

ELDN is the stock ticker symbol of Eledon Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Eledon Pharmaceuticals, Inc. is 127.06 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check ELDN's fair value in chart for subscribers.

The fair value guage provides a quick view whether ELDN is over valued or under valued. Whether Eledon Pharmaceuticals, Inc. is cheap or expensive depends on the assumptions which impact Eledon Pharmaceuticals, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ELDN.

As of Wed Jan 28 2026, ELDN's PE ratio (Price to Earnings) is -1.59 and Price to Sales (PS) ratio is 718.31. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ELDN PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Eledon Pharmaceuticals, Inc. has provided -0.46 (multiply by 100 for percentage) rate of return.